Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

QuANTUM-Wild Trial to Explore Correlative Outcomes With Quizartinib in FLT3-Negative AML

March 18th 2025

David M. Swoboda, MD, discusses data with quizartinib in FLT3-negative AML from the QUIWI trial and the rationale for the QuANTUM-Wild trial.

Minimally Invasive Surgical Approaches Are a Convenient and Effective CRC Management Option

March 18th 2025

Andreas M. Kaiser, MD, discusses the differences between minimally invasive surgical approaches for colorectal cancer in community vs academic settings.

Dr Rampal on ​Emerging Therapies Under Investigation in Myelofibrosis

March 17th 2025

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD

March 17th 2025

Ashkan Emadi, MD, PhD, discusses how the combination of venetoclax plus pegcrisantaspase induced complete remissions in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.

Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer

March 17th 2025

Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.

BVAC-C Vaccine Therapy Plus Durvalumab Elicits Responses in Recurrent HPV+ Cervical Cancer

March 16th 2025

BVAC-C was effective with a manageable safety profile when combined with durvalumab in patients with recurrent HPV-positive cervical cancer.

Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer

March 16th 2025

Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

Dr Koehne on ​the Evolution of the Multiple Myeloma Treatment Paradigm

March 14th 2025

Guenther Koehne, MD, discusses the roles of ASCT, CAR T-cell therapy, and bispecific antibodies in the treatment of patients with multiple myeloma.

Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL

March 13th 2025

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in ​relapsed/refractory LBCL.

Pembrolizumab Produces Durable Responses in Chemo-Pretreated Clear Cell Gynecologic Cancers

March 13th 2025

Treatment with pembrolizumab monotherapy was effective and well tolerated in pretreated patients with advanced clear cell gynecologic cancers.

Nadofaragene Firadenovec May Propel Advances in Intermediate-Risk NMIBC Management

March 13th 2025

Neal D. Shore, MD, FACS, discusses the evaluation of nadofaragene firadenovec in intermediate-risk NMIBC and its potential effect on treatment strategies.

FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

March 13th 2025

Nataliya Uboha, MD, PhD, discusses the FDA approval of first-line tislelizumab-jsgr with platinum-containing chemotherapy for unresectable or metastatic ESCC.

Dr DeAngelo on the Efficacy of Avapritinib in Advanced Systemic Mastocytosis

March 13th 2025

Daniel J. DeAngelo, MD, PhD, discusses the clinical implications of findings from the PATHFINDER trial of avapritinib in advanced ​​systemic mastocytosis.

BLA Accepted in China for Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

March 13th 2025

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

March 13th 2025

177Lu rhPSMA-10.1 injection led to proportionally higher absorbed radiation doses in tumors vs healthy tissues in patients with mCRPC.

Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

March 12th 2025

Drs. Grivas and Park discuss developments in bladder cancer research, including the potential of HER2-targeted therapies and PD-1/PD-L1 inhibitors in the neoadjuvant setting.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors

March 11th 2025

The feasibility and safety of treatment with SAR443216 support the further investigation of this agent in patients with advanced HER2-positive tumors.

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

March 11th 2025

Cema-cel generated CRs, most of which were durable, among patients with relapsed/refractory LBCL who were naive to anti-CD19 CAR T-cell therapy.

Dr Davila on ​the Clinical Implications of Tumor Driver and Immune Escape Research in LBCL

March 10th 2025

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

NEXT PAGE
PREVIOUS PAGE
x